B cell maturation antigen–specific (BCMA-specific) chimeric antigen receptor T cell (CAR-T cell) therapies are associated with high response rates in relapsed/refractory MM (RRMM) (12, 13). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.